Stay updated with breaking news from Outlayer Item. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SAN FRANCISCO — Lebrikizumab reduced exacerbations in adolescents with uncontrolled asthma and had a favorable safety profile, according to results of the ACOUSTICS study.The study, which was stopped early by the sponsor, showed a greater treatment effect with the higher dose of lebrikizumab studied.
Suicide risk prediction in adults was optimized when utilizing both in-person screening and electronic data, according to a study published in JAMA Network Open. “Mental health diagnoses are often absent in records of those who subsequently die from suicide. Better risk identification and prognostication might improve outreach and prevention,” Drew Wilimitis, BS, of the department of
Almirall S.A. and Inserm Transfert have entered an agreement to advance research in vitiligo treatment, the two entities announced in a press release.The licensing and research collaboration agreement will focus on developing medicines that modulate the Wnt pathway.
SAN FRANCISCO — A session at the American Thoracic Society International Conference highlighted a new clinical practice guideline addressing idiopathic pulmonary fibrosis and progressive pulmonary fibrosis in adults. The new guidance comes nearly 4 years after the last guidance on the diagnosis and management of IPF, according to the ATS.
Travere Therapeutics Inc. announced the FDA has accepted and granted priority review of its new drug application under subpart H for accelerated approval of sparsentan for treatment of IgA nephropathy.According to the company press release, sparsentan is a dual endothelin angiotensin receptor antagonist that targets the endothelin A receptor and the angiotensin II subtype 1 receptor.